(Q37879155)

24 August 2017

1 reference

title

Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment (English)

1 reference

age related macular degeneration

24 August 2017

0 references

1 reference

1 reference

based on heuristic

inferred from title

author name string

Georges M El-Mollayess

series ordinal

1

1 reference

24 August 2017

Baha' N Noureddine

series ordinal

2

1 reference

24 August 2017

Ziad F Bashshur

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

Seminars in Ophthalmology

24 August 2017

published in

1 reference

24 August 2017

volume

26

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

69-76

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

24 August 2017

1 reference

The role of oxidative stress in the pathogenesis of age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Angiographic-histological correlation of late exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Are low inflammatory reactions involved in exudative age-related macular degeneration? Morphological and immunhistochemical analysis of AMD associated with basal deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Update on the genetics of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Macrophage depletion inhibits experimental choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Molecular and biological properties of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

MMP-2 and MMP-9 secretion by rpe is stimulated by angiogenic molecules found in choroidal neovascular membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Testing intravitreal toxicity of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the Pan-American Collaborative Retina Study Gro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Bevacizumab local complications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Expression of hypoxia-inducible factor-1alpha and -2alpha in human choroidal neovascular membranes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Localisation of SDF-1 and its receptor CXCR4 in retina and choroid of aged human eyes and in eyes with age related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Contribution of bone-marrow-derived cells to choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Endostatin: the logic of antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

SDF1-alpha is associated with VEGFR-2 in human choroidal neovascularisation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2010.545100

10.3109/08820538.2010.545100

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference